CTPharma Launches FDA-Approved Medical Cannabis Clinical Studies With Human Subjects - cannabisbusinesstimes.com
CTPharma has launched FDA-approved medical cannabis clinical studies with human subjects, signaling potential regulatory progress for cannabis-based pharmaceuticals.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 8, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) involved in pharmaceutical manufacturing. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline specified.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
CTPharma initiated FDA-approved clinical studies for medical cannabis with human subjects, indicating a step toward potential FDA approval of cannabis-derived drugs.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) involved in pharmaceutical manufacturing.
What you must do
Monitor the progress of these clinical studies and assess potential implications for your own product development or manufacturing strategies.
Deadline
No immediate deadline specified.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- The FDA let substandard factories ship these medications to the U.S. - michiganadvance.com
- Tom’s of Maine says it will remedy mold, bacteria problems found by FDA at Sanford plant - mainebiz.biz
- The FTC Challenges Companies’ Allegedly Improper Orange Book Patent Listings - skadden.com
- Alabama Board of Medical Examiners Issues Warning of Non-FDA-Approved Peptides - drugtopics.com
- Psychedelics Policy Newsletter: DEA considers rescheduling psilocybin, FDA releases rejection decision, and more - reason.org